BCRX logo

BCRX
Biocryst Pharmaceuticals Inc.

36,608
Mkt Cap
$2.13B
Volume
4.26M
52W High
$11.31
52W Low
$6.00
PE Ratio
7.06
BCRX Fundamentals
Price
$8.38
Prev Close
$8.49
Open
$8.50
50D MA
$7.33
Beta
0.89
Avg. Volume
4.48M
EPS (Annual)
$1.21
P/B
-15.18
Rev/Employee
$2.01M
$1,907.31
Loading...
Loading...
News
all
press releases
BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by GW&K Investment Management LLC
GW&K Investment Management LLC decreased its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 16.2% in the 3rd quarter, according to its most recent Form 13F filing...
MarketBeat·6d ago
News Placeholder
More News
News Placeholder
BioCryst Pharmaceuticals Conference: Profitability Pivot, ORLADEYO Growth, Navenibart Phase 3 Timeline
BioCryst Pharmaceuticals (NASDAQ:BCRX) executives highlighted the company's transition to profitability, continued growth of its hereditary angioedema (HAE) franchise, and progress on newly acquired...
MarketBeat·7d ago
News Placeholder
BioCryst Pharmaceuticals, Inc. $BCRX Shares Sold by Fisher Asset Management LLC
Fisher Asset Management LLC cut its stake in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 5.4% in the third quarter, according to the company in its most recent disclosure with the...
MarketBeat·8d ago
News Placeholder
BioCryst Pharmaceuticals, Inc. $BCRX Stock Holdings Boosted by Vanguard Group Inc.
Vanguard Group Inc. lifted its position in BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 6.1% during the third quarter, according to its most recent 13F filing with the SEC. The...
MarketBeat·10d ago
News Placeholder
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading Up 10.7% After Earnings Beat
BioCryst Pharmaceuticals (NASDAQ:BCRX) Trading 10.7% Higher on Better-Than-Expected Earnings...
MarketBeat·14d ago
News Placeholder
BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX) Given Consensus Recommendation of "Moderate Buy" by Brokerages
Shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Get Free Report) have been given an average recommendation of "Moderate Buy" by the thirteen analysts that are presently covering the stock...
MarketBeat·14d ago
News Placeholder
BioCryst Pharmaceuticals (NASDAQ:BCRX) Posts Quarterly Earnings Results, Beats Expectations By $1.05 EPS
BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) posted its quarterly earnings results on Thursday. The biotechnology company reported $1.12 earnings per share (EPS) for the quarter, beating...
MarketBeat·15d ago
News Placeholder
BioCryst Pharmaceuticals (BCRX) Q4 Earnings and Revenues Surpass Estimates
BioCryst (BCRX) delivered earnings and revenue surprises of +1,623.08% and +172.17%, respectively, for the quarter ended December 2025. Do the numbers hold clues to what lies ahead for the stock?
Zacks·15d ago
News Placeholder
BioCryst Pharmaceuticals Q4 Earnings Call Highlights
BioCryst Pharmaceuticals (NASDAQ:BCRX) outlined its full-year 2025 performance and priorities for 2026 during its fourth-quarter conference call, highlighting strong growth for its hereditary...
MarketBeat·15d ago
News Placeholder
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up After Better-Than-Expected Earnings
BioCryst Pharmaceuticals (NASDAQ:BCRX) Shares Gap Up on Strong Earnings...
MarketBeat·15d ago
<
1
2
...
>

Latest BCRX News

View
Top Discussions

Advertisement|Remove ads.

Advertisement|Remove ads.